6 Amendments of Salvatore DE MEO related to 2023/2075(INI)
Amendment 188 #
Motion for a resolution
Recital H a (new)
Recital H a (new)
Ha. whereas thanks to research knowledge about the biology of many types of non-communicable diseases, such as neurodegenerative ones, has grown exponentially, but has not yet been translated into decisive therapeutic interventions, and is still limited to purely symptomatic interventions;
Amendment 367 #
Motion for a resolution
Paragraph 7 – point b
Paragraph 7 – point b
b. Promote evidence-based and proportionate measures aimed at reducing and preventing alcohol-related harm within the revised EU alcohol strategy;
Amendment 405 #
Motion for a resolution
Paragraph 8 – point a
Paragraph 8 – point a
a. encourage and help consumers to make informed and healthy choices about food products, empowering them to follow healthy, varied and balanced diets; promote behavioural changes via communication and mass media campaigns for healthy diets; encourage public food procurement and service policies for healthy and sustainable diets;
Amendment 411 #
Motion for a resolution
Paragraph 8 – point a a (new)
Paragraph 8 – point a a (new)
aa. implement a comprehensive strategy to combat eating disorders, through allocation of resources, data collection, prevention campaigns as well as support systems and coordination with existing bodies in individual Member States;
Amendment 589 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. stresses the complexity of diagnosis in certain non-communicable diseases in childhood, such as Multiple Sclerosis, whose onset may be similar to that found in other inflammatory diseases of the central nervous system, stresses that diagnosis is crucial for the delivery of targeted and effective therapies;
Amendment 732 #
Motion for a resolution
Paragraph 22
Paragraph 22
22. Welcomes the pharmaceutical package and calls for the strengthening of the European medicines market to ensure access to medicines and alleviate medicine shortages, reduce barriers to cross-border business, while strengthening incentives for investment in innovation; underlines that in many cases the immediate availability of precise and appropriate medicines can hinder the irreversible degeneration of certain diseases; underlines that data protection and intellectual property rights are crucial to ensure competitiveness in the EU by incentivising innovators to develop new products and further ongoing research efforts;